Loading patent…
AssigneeSociete des Produits Nestle S.A.
InventorsVINCENZO SORRENTINO, SONIA KARAZ, MAXIMILIAN VON EYNATTEN, CLAUDIA ROESSLE, JEROME FEIGE
Estimating the term…
The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions comprising urolithin for increasing the urinary creatinine and/or for decreasing the albumin/creatinine ratio and/or for increasing the albumin reabsorption. In addition, methods and compositions comprising urolithin to improve the lean mass of a muscle and/or to improve the muscle fiber size and/or to improve the level of at least one amino acid are disclosed. Also disclosed are methods and compositions comprising urolithin to improve the level of at least one metabolic product and/or to improve the level of at least one nucleotide and/or to improve the level of at least one nicotinamide adenine dinucleotide and/or to increase the level of glutathione (GSH) and/or glutathione disulfide (GSSG) and/or to increase the level of succinate and/or malate and/or to increase the level of phosphocreatine.
A method of treating and/or preventing a disease or condition associated with muscle decline and/or a kidney dysfunction, the method comprising administering to a subject in need thereof an effective amount of a composition comprising urolithin or an urolithin or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
8-9. (canceled)
A method for improving the lean mass of a muscle in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a composition comprising urolithin or an urolithin or a pharmaceutically acceptable salt thereof.
12-13. (canceled)
15-18. (canceled)
A method for increasing the albumin reabsorption in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a composition comprising urolithin or an urolithin or a pharmaceutically acceptable salt thereof.
(canceled)
27-160. (canceled)
Dependencies are inferred from the claim text.